Euretos

Executive Summary

Euretos is a Netherlands-based AI-driven drug discovery company that has developed a comprehensive biological knowledge graph integrating literature, patents, experimental, clinical, and real-world patient data. Founded in 2012, the company offers ready-to-use applications and workflows that enable efficient desk research, experiment design, and observation analysis. By leveraging this vast integrated dataset, Euretos aims to accelerate the drug discovery process, reduce costs, and improve success rates. Despite being in an early phase (Phase 1), the company's unique approach to consolidating heterogeneous biomedical data positions it as a promising player in the AI drug discovery space. However, with limited public information on funding, valuation, and commercial traction, Euretos faces typical risks of pre-revenue biotech startups, including execution challenges and competitive pressure from established players.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership with Major Pharma Company40% success
• Q2 2026Series A Funding Round Completion50% success
• Q3 2026Launch of New AI-Powered Target Discovery Module60% success